CompletedNot Applicable

The Resting-state EEG Gamma Oscillations in Alzheimer's Disease

Turkey (Türkiye)51 participantsStarted 2012-11-07

Plain-language summary

The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology. The present study aims to investigate resting-state gamma activity changes in Cerebrospinal fluid (CSF)-proven early-onset Alzheimer's disease (EOAD) patients with a holistic approach that employs structural and functional brain neuroimaging techniques, and neuropsychological aspects.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * For all participants: Age \< 65 * For EOAD patients: Meeting National Institute on Aging-Alzheimer's Association diagnostic criteria. * For healthy controls: Mini-Mental State Examination (MMSE) \>25 Instrumental Activities of Daily Living Scale (IADL) = 8 Exclusion Criteria: * For EOAD patients: MMSE \> 24 Geriatric depression scale (GDS) \> 14 Having treatment with antipsychotics and comorbidities that may affect cognitive abilities. * For healthy controls: Having neurological and/or cognitive abnormalities Having a history of neurological, psychiatric, or systemic disorders, and alcohol/drug abuse. GDS \> 14 * For all participants: Having neurological (other than AD) or any other serious disease (cancer, systemic disease)

What they're measuring

EEG

Timeframe: Day 2

Trial details

NCT IDNCT05989087

SponsorGörsev Yener, MD, PhD

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-01-02

View on ClinicalTrials.gov More Alzheimer Disease, Early Onset trials